Drug Type Small molecule drug |
Synonyms Avalide, Avapro HCT, CoAprovel + [14] |
Target |
Mechanism AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), NCC inhibitors(Thiazide-sensitive sodium-chloride cotransporter inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (30 Sep 1997), |
RegulationPriority Review (CN) |
Molecular FormulaC32H36ClN9O5S2 |
InChIKeyNZPSYYOURGWZCM-UHFFFAOYSA-N |
CAS Registry448264-66-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Essential Hypertension | EU | 14 Oct 1998 | |
Essential Hypertension | IS | 14 Oct 1998 | |
Essential Hypertension | LI | 14 Oct 1998 | |
Essential Hypertension | NO | 14 Oct 1998 | |
Hypertension | US | 30 Sep 1997 |
Phase 4 | 833 | (Early titration group) | pkadvsiqor(ulxrdvxeii) = Serious adverse events were more frequent in E (2.5% vs 0.7%) ecdhxtxmmj (erqueuugwb ) | - | 01 Dec 2011 | ||
(Late titration group) | |||||||
Not Applicable | 833 | Early titration group (E) | ybmbuahtke(lesycqjnin) = ivpkvquauu ohebzhqhhb (mvnnvogadn ) View more | Positive | 01 Jun 2010 | ||
Late titration group (L) | ybmbuahtke(lesycqjnin) = ezjfdazrgl ohebzhqhhb (mvnnvogadn ) View more |